Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Stock Information for Humanigen Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Humanigen Inc.

Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
Humanigen Reports Third Quarter 2022 Financial Results
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference
Humanigen Announces Retention of SC&H Capital as Financial Advisor
DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 25, 2022 in Humanigen Lawsuit - HGEN
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Humanigen, Inc. (HGEN) Investors of Class Action and Last Few Hours to Actively Participate

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.